Digest Network Come funziona
Network
/
Società
Ki
Non verificato

Kinaset Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

4 comunicati stampa

Guarda tutti i comunicati
20/07/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Sanità
Kinaset Therapeutics Announces First Patient Dosed in Phase 2b PANAIRAMA Trial of frevecitinib (KN-002) in Patients with Severe Asthma
Fonte
Kinaset Therapeutics, Inc.
Emittente
Business Wire
1.00
0
30/06/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Kinaset Therapeutics Appoints Daniel G. Welch as Board Chair and David Lubner as Independent Director and Audit Committee Chair
Fonte
Kinaset Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/01/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases
Fonte
Kinaset Therapeutics, Inc.
Emittente
Business Wire
1.00
0
29/01/2025
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Industria
Kinaset Therapeutics Announces FDA Clearance of IND Application for frevecitinib (KN-002) in Asthma Treatment
Fonte
Kinaset Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0